Walgreens has agreed to pay $100 million to settle a class action lawsuit related to drug pricing practices, as part of a broader initiative involving a multistate coalition aimed at holding pharmaceutical companies accountable for inflated drug costs. This settlement is expected to benefit thousands of individuals affected by these pricing issues. Additionally, a recent False Claims Act settlement of $21.75 million was reached, highlighting ongoing efforts to combat prescription drug fraud. Legal experts emphasize the importance for life sciences companies to reassess their compliance practices to avoid allegations under the Anti-Kickback Statute (AKS) and to prepare defenses against potential qui tam actions by whistleblowers. Recent court rulings have also mandated that the government compensate relators from these FCA settlements, further underscoring the role of whistleblower protections in healthcare litigation.